Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade |
Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-30 15:01:14 |
Czytaj oryginał (ang.) |
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement |
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function |
globenewswire.com |
2024-12-23 10:37:00 |
Czytaj oryginał (ang.) |
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement |
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function |
globenewswire.com |
2024-12-23 10:30:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Reports Third Quarter 2024 Financial Results |
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter |
globenewswire.com |
2024-11-07 10:30:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Reports Second Quarter 2024 Financial Results |
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter |
globenewswire.com |
2024-08-08 20:15:00 |
Czytaj oryginał (ang.) |
Best Momentum Stocks to Buy for July 12th |
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024. |
zacks.com |
2024-07-12 15:15:24 |
Czytaj oryginał (ang.) |
New Strong Buy Stocks for July 12th |
USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024. |
zacks.com |
2024-07-12 11:40:17 |
Czytaj oryginał (ang.) |
UPDATE – Ikena Oncology Announces Strategic Update |
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. |
globenewswire.com |
2024-05-28 20:42:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Announces Strategic Update |
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. |
globenewswire.com |
2024-05-28 20:15:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update |
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline. |
globenewswire.com |
2024-05-13 20:45:00 |
Czytaj oryginał (ang.) |
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum |
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. |
globenewswire.com |
2024-04-10 12:00:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results |
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline. |
globenewswire.com |
2024-03-12 10:00:00 |
Czytaj oryginał (ang.) |
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference |
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference. |
globenewswire.com |
2024-02-27 10:00:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer |
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise |
globenewswire.com |
2024-02-21 18:15:00 |
Czytaj oryginał (ang.) |
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-02-14 12:37:05 |
Czytaj oryginał (ang.) |
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround |
Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-01-24 12:36:06 |
Czytaj oryginał (ang.) |
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates |
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical development of IK-930 and IK-595 Ended 2023 in strong financial position with approximately $175 million in cash; runway extended into 2H 2026 BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The Company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. |
globenewswire.com |
2024-01-18 18:05:00 |
Czytaj oryginał (ang.) |
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results |
Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions |
globenewswire.com |
2023-11-09 09:00:00 |
Czytaj oryginał (ang.) |
Ikena Oncology to Present at Multiple November 2023 Investor Conferences |
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November. |
globenewswire.com |
2023-11-07 10:00:00 |
Czytaj oryginał (ang.) |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) |
NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://zlk.com/compensation2/ikena-oncology-inc-lawsuit-submission-form or contact Joseph E. |
prnewswire.com |
2023-10-02 09:45:00 |
Czytaj oryginał (ang.) |